To date Parkinson’s disease (PD) is diagnosed clinically and rather late in the course of the disease. There is an urgent need to find an objective, quantifiable biomarker for the diagnosis of this highly prevalent movement disorder. Researchers have now found initial evidence that a blood test to detect the alpha-synuclein protein is a viable, less invasive option to diagnose PD. The study appears in the Journal of Parkinson’s Disease, published by IOS Press, now part of Sage.
More drug and device patents were invalidated for bad info than those filed by other industries, analysis finds
The patents on medicines and devices approved by the U.S. Food and Drug Administration were more frequently invalidated due to information misrepresented or withheld from